Stock BAYN BAYER AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra
Other stock markets
 16:39:04 26/04/2024 BST 		5-day change 1st Jan Change
27.4 EUR +1.88% Intraday chart for Bayer AG +4.08% -18.53%
04-26 Bayer CEO wins first AGM shareholder vote RE
04-26 BAYER SAYS INVESTORS WITH 91.69% OF EQUITY CAPITAL REPRESENTED A… RE

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 71,530 47,309 46,174 47,476 33,039 26,918 - -
Enterprise Value (EV) 1 105,598 84,884 79,140 78,749 33,039 60,024 56,585 53,036
P/E ratio 17.5 x -4.51 x 46.1 x 11.5 x -11.2 x 12.5 x 8.43 x 7.98 x
Yield 3.85% 4.15% 4.26% 4.97% - 0.4% 0.85% 3.88%
Capitalization / Revenue 1.64 x 1.14 x 1.05 x 0.94 x 0.69 x 0.57 x 0.56 x 0.55 x
EV / Revenue 2.43 x 2.05 x 1.8 x 1.55 x 0.69 x 1.27 x 1.18 x 1.09 x
EV / EBITDA 9.18 x 7.41 x 7.08 x 5.83 x 3.11 x 5.8 x 5.16 x 4.81 x
EV / FCF 19 x 34.2 x 31.9 x 19 x - 15.1 x 11 x 11.7 x
FCF Yield 5.26% 2.93% 3.13% 5.26% - 6.64% 9.12% 8.56%
Price to Book 1.51 x 1.55 x 1.4 x 1.22 x - 0.77 x 0.71 x 0.65 x
Nbr of stocks (in thousands) 982,424 982,424 982,424 982,424 982,424 982,424 - -
Reference price 2 72.81 48.16 47.00 48.32 33.63 27.40 27.40 27.40
Announcement Date 27/02/20 25/02/21 01/03/22 28/02/23 05/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 43,545 41,400 44,081 50,739 47,637 47,113 47,964 48,721
EBITDA 1 11,503 11,461 11,179 13,513 10,632 10,344 10,968 11,027
EBIT 1 7,007 7,095 7,295 9,257 7,589 6,625 7,102 7,162
Operating Margin 16.09% 17.14% 16.55% 18.24% 15.93% 14.06% 14.81% 14.7%
Earnings before Tax (EBT) 1 2,880 -17,250 2,046 4,670 -1,621 3,252 4,017 4,481
Net income 1 4,091 -10,495 1,000 4,150 -2,941 2,081 3,167 3,417
Net margin 9.39% -25.35% 2.27% 8.18% -6.17% 4.42% 6.6% 7.01%
EPS 2 4.170 -10.68 1.020 4.220 -2.990 2.190 3.251 3.434
Free Cash Flow 1 5,557 2,485 2,478 4,144 - 3,985 5,161 4,538
FCF margin 12.76% 6% 5.62% 8.17% - 8.46% 10.76% 9.31%
FCF Conversion (EBITDA) 48.31% 21.68% 22.17% 30.67% - 38.53% 47.06% 41.15%
FCF Conversion (Net income) 135.83% - 247.8% 99.86% - 191.52% 162.97% 132.82%
Dividend per Share 2 2.800 2.000 2.000 2.400 - 0.1106 0.2326 1.064
Announcement Date 27/02/20 25/02/21 01/03/22 28/02/23 05/03/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2020 S2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1
Net sales 1 22,899 18,501 9,781 11,118 14,639 12,819 11,281 12,000 14,389 11,044 10,342 11,862 14,174 11,038 25,032 10,398 11,892 22,305 -
EBITDA 1 7,274 - 2,089 2,395 5,251 3,349 2,451 2,462 4,471 2,527 1,685 3,023 4,279 2,408 6,559 1,691 2,444 4,109 -
EBIT 1 - - 1,224 1,383 4,172 2,280 1,352 1,453 3,404 1,534 709 1,942 2,513 1,679 - 1,595 - - -
Operating Margin - - 12.51% 12.44% 28.5% 17.79% 11.98% 12.11% 23.66% 13.89% 6.86% 16.37% 17.73% 15.21% - 15.34% - - -
Earnings before Tax (EBT) - - 194 1,497 3,722 -523 601 870 2,606 -1,574 -4,297 1,644 - - - - - - -
Net income 1 - - 85 1,161 3,291 -298 546 611 2,178 -1,887 -4,569 1,337 1,438 500.3 2,308 23.78 167.1 422 -
Net margin - - 0.87% 10.44% 22.48% -2.32% 4.84% 5.09% 15.14% -17.09% -44.18% 11.27% 10.14% 4.53% 9.22% 0.23% 1.41% 1.89% -
EPS 2 - - 0.0900 1.180 3.350 -0.3000 0.5600 0.6200 2.220 -1.920 -4.660 1.360 1.464 0.5076 2.350 0.0225 0.1722 0.4300 -
Dividend per Share 2 - - - 2.000 - - - 2.400 - - - - 0.0275 0.0275 - 0.0275 0.0275 - 0.0275
Announcement Date 04/08/20 25/02/21 09/11/21 01/03/22 10/05/22 04/08/22 08/11/22 28/02/23 11/05/23 08/08/23 08/11/23 05/03/24 - - - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 34,068 37,575 32,966 31,273 - 33,105 29,667 26,117
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.962 x 3.279 x 2.949 x 2.314 x - 3.2 x 2.705 x 2.368 x
Free Cash Flow 1 5,557 2,485 2,478 4,144 - 3,985 5,161 4,538
ROE (net income / shareholders' equity) 13.5% 16.2% 20.1% 8.65% - 14.5% 15% 13.6%
ROA (Net income/ Total Assets) 3.23% -8.63% 0.84% 3.39% - 0.77% 1.58% 2.6%
Assets 1 126,495 121,611 118,526 122,560 - 269,267 200,537 131,321
Book Value Per Share 2 48.20 31.10 33.60 39.50 - 35.50 38.40 42.40
Cash Flow per Share 2 8.360 4.990 5.180 7.220 - 7.520 9.190 8.050
Capex 1 2,650 2,418 2,611 2,949 - 2,997 2,917 3,014
Capex / Sales 6.09% 5.84% 5.92% 5.81% - 6.36% 6.08% 6.19%
Announcement Date 27/02/20 25/02/21 01/03/22 28/02/23 05/03/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bayer AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
27.4 EUR
Average target price
36.9 EUR
Spread / Average Target
+34.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BAYER AG Stock Bayer AG
-18.53% 28.74B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BAYN Stock
  4. Financials Bayer AG